Aldeyra Therapeutics has patented a method for treating retinitis pigmentosa using an intravitreal composition of methotrexate, sucrose, and phosphate buffer. The composition reduces secondary punctate keratitis incidence by 10-50% compared to non-GMP methotrexate. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of April 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of retinitis pigmentosa with methotrexate eye injections
A recently granted patent (Publication Number: US11911385B1) discloses a method for treating retinitis pigmentosa (RP) by administering a specific composition intravitreally to a subject in need. The composition includes methotrexate at a concentration ranging from about 5 mg/mL to 12 mg/mL, sucrose at a concentration of about 7% w/v to 12% w/v, and a phosphate buffer. The volume of the composition administered falls within the range of about 20 µL to 300 µL. This method aims to inhibit and relieve RP while reducing the incidence of secondary punctate keratitis by 10% to 50% compared to subjects receiving non-GMP methotrexate compositions or those with volumes exceeding 300 µL.
Furthermore, the patent claims highlight specific variations within the method, such as administering a volume of 50 µL±10 µL, which has shown to reduce secondary punctate keratitis by about 20% to 40%. The method also demonstrates a statistically significant reduction in punctate keratitis incidence across a representative group of subjects, with the volume of composition administered ranging from 20 µL to 80 µL. Additionally, the method addresses the incidence of intraocular pressure (IOP) elevation and transit rate of the composition in silicone oil, emphasizing the precise concentrations and parameters required for optimal treatment outcomes. Overall, the patent provides detailed guidelines for the effective treatment of RP using the disclosed composition, offering potential advancements in managing this ocular condition.
To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
